Cephalon to Terminate Provigil Promotion Deal with Takeda Pharmaceuticals North America.
Cephalon Inc. has provided written notice to Takeda Pharmaceuticals North America Inc. that as of November 1 Cephalon is ending its co-promotion agreement covering its sleep disorder drug Provigil. Cephalon of Frazer, Pa., had the right to terminate the deal if net sales of Provigil did not exceed an agreed upon level during the second year of the agreement. As a result of the termination, Cephalon will be required to make payments, the amount of which was not disclosed, to Takeda for the next three years. The payments will be based on a percentage of royalties paid to Takeda during the final year of the agreement.
